Protara Therapeutics (NASDAQ:TARA – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Monday, Benzinga reports. They currently have a $23.00 target price on the stock.
Separately, Oppenheimer upped their price target on shares of Protara Therapeutics from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Monday, April 22nd.
Read Our Latest Analysis on TARA
Protara Therapeutics Stock Performance
Protara Therapeutics (NASDAQ:TARA – Get Free Report) last issued its quarterly earnings results on Wednesday, March 13th. The company reported ($0.90) earnings per share for the quarter, beating the consensus estimate of ($1.03) by $0.13. As a group, sell-side analysts predict that Protara Therapeutics will post -3.55 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Protara Therapeutics stock. Oppenheimer & Co. Inc. bought a new position in shares of Protara Therapeutics, Inc. (NASDAQ:TARA – Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 10,000 shares of the company’s stock, valued at approximately $40,000. Oppenheimer & Co. Inc. owned 0.09% of Protara Therapeutics as of its most recent SEC filing. 38.13% of the stock is currently owned by hedge funds and other institutional investors.
Protara Therapeutics Company Profile
Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Recommended Stories
- Five stocks we like better than Protara Therapeutics
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Garmin Navigates to New Highs Driven By Wearables Trend
- What is a Secondary Public Offering? What Investors Need to Know
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- CD Calculator: Certificate of Deposit Calculator
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Protara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.